Browse the evidence

Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).

Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.

Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.

Practitioners should emphasize lifestyle changes in addition to pharmacotherapy for optimal management.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Plant-based dietary patterns rich in minimally processed foods, vegetables, and fruits reduce CVD risk.

Health professionals should recommend plant-based diets rich in whole foods to reduce CVD risk.

The Mediterranean, Dietary Approaches to Stop Hypertension, and vegetarian diets reduce CVD risk.

Health professionals should promote these specific dietary patterns to lower CVD risk.

Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5% to 20.9% across different trials in a dose-dependent manner.

Tirzepatide may be an effective option for weight management in patients with obesity and T2DM.

Tirzepatide significantly decreased food intake and reduced overall appetite scores.

Tirzepatide may help reduce appetite, aiding in weight loss efforts.

Tirzepatide exhibited favorable effects on glycemic control, with reductions in HbA1c levels ranging from 20.4 mmol/mol with the 5 mg dose to 28.2 mmol/mol with the 15 mg dose.

Tirzepatide may improve glycemic control in patients with T2DM.

Semaglutide led to a weight reduction of 9.21 kg in the study population.

Semaglutide may assist in significant weight loss for patients in this demographic.

The working group recommends dietary consultations, increased physical activity, resistance training, and potential use of oral nutritional supplements and medications for managing sarcopenic obesity.

Practitioners should consider these recommendations for effective management of sarcopenic obesity.

Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control.

These agents may be effective options for patients needing weight loss and glycemic control.

Excess accumulation of visceral adipose tissue (VAT) leads to the clustering of cardiometabolic risk factors.

Reducing visceral fat may help mitigate cardiometabolic risks.

Calorie restriction, structured exercise, pharmacotherapy, and metabolic surgeries have shown beneficial effects in reducing VAT.

Implementing these strategies can effectively reduce visceral fat.

After 3 months, average weight loss was 4.11 kg or 4.57%.

Practitioners can expect significant weight loss in patients using semaglutide in a real-world setting.

Individuals lost fat mass (2.67 kg) and trunk fat mass (1.10 kg).

Practitioners can expect reductions in fat mass among patients using semaglutide.

Body composition improved with losses in fat mass and gains in overall proportion of lean muscle and skeletal muscle.

Practitioners can expect improvements in body composition with semaglutide treatment.

Exercise has emerged as a potent therapeutic in disease states characterized by the accelerated aging phenotype.

Implementing exercise programs can be crucial for managing diseases associated with aging.

NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.

NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.

GLP-1s reduce body weight by 5% to 18% in trials.

Clinicians can expect significant weight loss in patients using GLP-1s.

Evidence-based nutritional and lifestyle strategies are crucial for effective GLP-1 treatment.

Clinicians should integrate nutritional and lifestyle interventions to enhance GLP-1 treatment outcomes.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

HU6 treatment for 19 weeks significantly decreased body weight by -2.86 kg compared to placebo (P = .003).

HU6 may be an effective treatment option for weight loss in patients with obesity-related HFpEF.

HU6 treatment significantly decreased total fat mass by -2.96 kg compared to placebo (P < .001).

HU6 may help reduce fat mass in patients with obesity-related HFpEF.

Consumers currently taking a GLP-1 consume significantly fewer calories than the other groups surveyed, with calorie reduction while taking a GLP-1 for weight loss estimated to be around 720 to 990 calories.

Practitioners should consider that GLP-1 users may have lower caloric intake, which could influence dietary recommendations.